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Membrane-type 1 matrix metalloproteinase (MT1-MMP) is expressed in different
types of invasive and proliferative cells, including cancer cells and stromal cells.
MT1-MMP cleaves extracellular matrix proteins, membrane proteins and other
pericellular proteins, thereby changing the cellular microenvironment and regu-
lating signal activation. Critical roles of protease activity in cancer cell prolifera-
tion, invasion and metastasis have been demonstrated by many groups. MT1-
MMP also has a non-protease activity in that it inhibits the oxygen-dependent
suppression of hypoxia-inducible factors (HIFs) via Munc18-1-interacting protein 3
(Mint3) and thereby enhances the expression of HIF target genes. Elevated HIF
activity in MT1-MMP-expressing cancer cells is a fundamental mechanism underly-
ing the Warburg effect, a well-known phenomenon where malignant cancer cells
exhibit a higher rate of glucose metabolism. Because specific intervention of HIF
activation by MT1-MMP suppresses tumor formation by cancer cells in mice, both
the proteolytic and non-proteolytic activities of MT1-MMP are important for
tumor malignancy and function in an integrated manner. In this review, we sum-
marize recent findings relating to how MT1-MMP activates HIF and its effects on
cancer cells and stromal cells.
T he extracellular matrix (ECM) is a fundamental componentof tissue architecture. During physiological and pathologi-
cal tissue remodeling, the ECM is degraded and replaced with
a newly formed ECM. Zinc-dependent proteinases, such as
matrix metalloproteinases (MMP), play a major role in ECM
turnover.(1,2) Although most MMP are secreted, some are
membrane-type (MT) MMP. Among them, MT1-MMP (also
known as MMP14) was the first membrane-anchored MMP
discovered to act as a potent protease that promotes cancer
invasion and metastasis.(3)
The activities of both soluble and MT MMP in cancer con-
tribute to loosening of the ECM. In contrast to soluble MMP,
the cell-surface localization of MT-MMP makes them suitable
for regulating signals in producer cells, as the cell surface is
the place where clusters of signaling molecules are formed.
MT1-MMP acts as a processing enzyme for many membrane
proteins, including cell-adhesion molecules, receptors, and
ligands such as growth factors and cytokines/chemokines, and
thereby regulates signals that promote cell motility, prolifera-
tion, and differentiation by altering the activities of the pro-
cessed substrate proteins.(1,2,4) For example, MT1-MMP cleaves
the extracellular ligand-binding domain of Eph receptor A2
(EphA2), a tyrosine kinase type receptor that shows ligand-
dependent inhibition activity of ErbB receptor signaling.(5,6)
The processing converts EphA2 into a ligand-independent
signal transducer that shows opposite activity of the ligand-
bound receptor by promoting cell motility.(5,6) MT1-MMP also
sheds CD44 and its homolog lymphatic vessel endothelial
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attrib
ution-NonCommercial License, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited and is not used for
commercial purposes.
Cancer Sci | 2017
hyaluronan receptor 1 and enhances cell motility(7) and lym-
phangiogenesis, respectively.(8) Likewise, biological feedback
due to MT1-MMP expression in producer cells reflects the
altered functions of the processed substrate proteins. Therefore,
the diverse functions of MT1-MMP in tissues reflect the
available substrates in the cellular microenvironment.(4)
While MT1-MMP is a potent membrane proteinase, it also has
activities that are independent of its catalytic activity.(9–13) For
example, MT1-MMP induces expression of the angiogenic vas-
cular endothelial growth factor (VEGF) and the cytoplasmic tail
(CPT), but not the catalytic domain, is responsible for the activ-
ity.(14,15) Analysis of macrophages derived from MT1-MMP-
knockout (MT1-KO) mice revealed that the levels of glycolytic
activity and VEGF production were greatly reduced compared to
those in wild-type macrophages.(12) These alterations in deficient
cells depended on the reduced activities of hypoxia-inducible fac-
tors (HIF). Indeed, HIF-1 activity in macrophages was high in
wild-type cells and low in MT1-KO cells, even during normox-
ia.(12) HIF are key transcription factors that mediate hypoxia-
induced stress responses and regulate the expression of hundreds
of genes, thereby affecting many cell functions, such as migra-
tion, invasion, proliferation, angiogenesis and cellular metabo-
lism.(16,17) Even though the oxygen-dependent suppression of
HIF activity during normoxia and its release upon exposure to
hypoxia has been studied extensively,(16,18) it remains largely
unclear whether and how HIF are activated during normoxia.
Therefore, it is of particular interest to determine how MT1-
MMP activates HIF during normoxia and what the biological
consequences of such activation might be.
MT1-MMP is a Key Regulator of Mesenchymal Cell Traits
Production of ECM components and their remodeling are largely
mediated by fibroblasts in tissue stromata.(19) MT1-MMP is usu-
ally expressed in activated fibroblasts and cancer cells, and
cleaves various ECMmolecules such as type-I collagen and lami-
nin.(2) The affected substrates are not restricted to the direct target
ECM proteins, as MT1-MMP triggers activation cascade of other
MMP, such as MMP-2, MMP-9 and MMP-13, by cleaving the
propeptide sequence of their latent forms.(4) Among the ECM
substrates, type I collagen is particularly important as it is the
major component forming the connective tissue architecture.(20)
Other than MT1-MMP, it has been shown that MMP-1, MMP-8
and MMP-13 also have collagenase activity and are responsible
for collagenolysis in the connective tissue space.(2) In contrast,
the collagenase activity of MT1-MMP is rather important for col-
lagenolysis-associated cellular functions, such as invasion and
cell proliferation.(4,21,22) The importance of the collagenolytic
activity has been experimentally demonstrated by MT1-MMP-
dependent cancer cell invasion and proliferation in 3-dimensional
collagen gels.(23,24) During invasion, MT1-MMP localizes at the
invasion front of cells where special cell membrane structures
known as invadopodia are formed, accompanying intracellular
actin reorganization.(25) Evidence suggests that particular mecha-
nisms exist to recruit MT1-MMP to invadopodia.(26,27) MT1-KO
mice displayed diverse defects related to aberrant collagen turn-
over such as fibrosis and dwarfism, indicating the importance of
the collagenase activity.(28,29) Altered stiffness of the ECM by
MT1-MMP also influences cellular conditions such as senes-
cence(30) and differentiation via the Hippo signaling pathway.(31)
Fully differentiated epithelial cells do not express MT1-
MMP, while activated stromal cells such as fibroblasts, stellate
cells, endothelial cells and macrophages do.(2) Cancerous cells
of epithelial origin, particularly invasive ones, also express
MT1-MMP.(2) Therefore, MT1-MMP expression is likely regu-
lated by signals that induce the epithelial–mesenchymal transi-
tion (EMT) or maintain the stromal cell phenotype. One of the
key regulators of EMT is a transcriptional suppressor, Snail,
that suppresses the expression of genes that maintain epithelial
cell traits (such as E-cadherin)(32,33) and that indirectly pro-
motes MT1-MMP expression.(34) Hypoxia is also an environ-
mental factor that promotes EMT and enhances the migratory
and invasive characteristics of cells.(32) HIF activated during
hypoxia upregulate MT1-MMP expression in cells.(35,36) Thus,
MT1-MMP expression and HIF activation may form a positive
feedback loop in mesenchymal cells and cancer cells (Fig. 1).
Based on the expression pattern and known functions of MT1-
MMP, it is plausibly an important key regulator of activated
mesenchymal cell and cancer cell traits.
Oxygen-dependent Suppression of Hypoxia-inducible
Factor Transcription Factors
The HIF family of transcription factors is composed of 3 mem-
bers; namely, HIF-1, HIF-2 and HIF-3, which can bind the
hypoxia response elements of target genes after the a and b
subunits heterodimerize.(18) All HIF use a common b subunit,
HIF-1b, but their respective a subunits are encoded by differ-
ent genes. The transcriptional activity of HIF is mediated by
the a subunits that bind the transcriptional co-factor p300/
CREB-binding protein (CBP) at the C-terminal activation
domain.(17) HIF-1a is expressed ubiquitously, whereas HIF-2a
and HIF-3a are tissue-specific.(18) The hallmark of HIFs is an
immediate activation upon exposure of cells to hypoxia.(16,18)
Both subunits are transcribed and translated constitutively, but
the activities of the a subunits are severely suppressed by oxy-
gen-dependent mechanisms at 2 different levels.(17,37) Quick
induction of HIF activity upon the exposure of cells to hypoxia
is simply attained by stopping the oxygen-dependent inhibition
against the a subunits.(17,18,38)
Two types of oxygen-dependent hydroxylases, prolyl hydroxy-
lase domain-containing (PHD1, 2 and 3) and factor-inhibiting
HIF-1 (FIH-1), introduce hydroxylation at the proline and aspara-
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Fig. 1. Schematic illustration showing how MT1-MMP activates
hypoxia-inducible factors (HIF) during normoxia. The cytoplasmic tail
(CPT) of MT1-MMP binds FIH-1 and promotes a stable FIH-1-Mint3
interaction. Mint3-bound FIH-1 cannot hydroxylate HIFa. Thus, MT1-
MMP activates HIF during normoxia. mTORC1 and NECAB3 also sup-
port the FIH-1-Mint3 interaction. HIF promotes the expression of many
genes, including MT1-MMP.
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hydroxylated proline residues of HIFa are recognized by the von
Hippel–Lindau tumor-suppressor protein, which successively
induces HIFa ubiquitination and proteasomal degradation. Thus,
PHD reduce HIFa protein levels greatly during normoxia.(17,37)
To ensure suppression of residual HIFa, FIH-1 hydroxylates the
asparagine residue of HIFa at the C-terminus transcriptional-acti-
vation domain to prevent HIFa from binding p300/CBP.(17,37)
Both mechanisms acting at different levels are important in sup-
pressing HIFa activity effectively. For example, the residual
level of HIFa that escapes proteasomal degradation is sufficient
to activate target genes when FIH-1 is absent.(39)
MT1-MMP Unlocks the Suppression of Hypoxia-inducible
Factors during Normoxia
It is well known that some types of cells exhibit HIF-1 activity
during normoxia, even when the expression levels of PHD and
FIH-1 are normal.(12,40,41) Invasive cancer cells often show
augmented glycolysis, exhibiting a phenomenon known as the
Warburg effect, a century-old observation for cancer cells.(42)
Data from many studies have shown that elevated HIF-1 activ-
ity serves as an underlying driving force of the Warburg effect
by upregulating expression of rate-limiting glycolytic enzymes
and transporters.(38) In addition to HIF-1, several oncogenic
signals in cancer cells also affect glycolytic pathways and con-
tribute to the Warburg effect.(43) Constitutive HIF-1 upregula-
tion is reminiscent of patients with Von Hippel–Lindau
disease, where the VHL tumor suppressor gene is inheritably
inactivated by mutation and promotes the development of dis-
ease-related tumors.(37) However, inactivating PHD, FIH-1 or
VHL mutations in tumors do not appear to be common based
on recent next-generation cancer-genome sequencing data.
These findings suggest that some other mechanisms may acti-
vate HIF transcription factors in cancer cells.
Enhanced glycolysis can be observed in some types of nor-
mal cells, such as macrophages and activated fibroblasts, dur-
ing normoxia.(44) In particular, macrophages produce most
ATP via glycolysis supported by elevated HIF-1 activity, while
many other cell types do via oxidative phosphorylation
(OXPHOS).(12,40) Interestingly, MT1-KO macrophages exhibit
a shortage of cellular ATP and a defect in ATP-dependent cell
functions.(11,12,45) In MT1-KO cells, the protein levels of HIF-
1, PHD and FIH-1 were not different from those in wild-type
macrophages, even though HIF-1 activity was markedly sup-
pressed.(12) Knockdown of genes related to HIF regulation in
macrophages demonstrated that FIH-1-dependent HIF-1 inhibi-
tion was specifically abrogated by MT1-MMP in the wild-type
cells.(12) Thus, MT1-MMP looks like an activator of HIF-1 by
inactivating FIH-1. Indeed, re-expression of MT1-MMP in
MT1-KO macrophages induced FIH-1 inactivation and pro-
moted HIF-1 activation.(12) FIH-1 suppressed HIF-2 as well;
therefore, MT1-MMP had a similar effect on HIF-2.(46,47)
The MT1-MMP-dependent mechanism of HIF-1 activation is
not restricted to macrophages. For example, cancer cells exhi-
bit clear correlations between MT1-MMP expression, FIH-1
inactivation, HIF-1 activation and the Warburg effect.(47,48)
However, differences in OXPHOS activities between macro-
phages and other cell types cause different effects of MT1-
MMP expression on ATP levels. In macrophages, MT1-MMP
depletion reduces ATP levels to less than 40% of normal cells,
although this effect was not as high in other cell types.(12,48)
MT1-MMP Employs Mint3/APBA3 to Inhibit FIH-1
Because the effect of MT1-MMP on HIF-1 can be observed in
different cell types,(11,12,47,48) it is of particular interest to
understand how MT1-MMP inactivates FIH-1 and whether it
is mediated by proteolytic activity against a specific substrate.
Domain analysis of MT1-MMP revealed that the CPT, but not
the protease domain, is responsible for HIF activation.(12) The
CPT showed binding activity to FIH-1, but did not affect the
enzymatic activity of FIH-1, at least in vitro.(12)
Munc18-1-interacting protein 3 (Mint3), also known as amy-
loid beta A4 precursor protein-binding family A member 3
(APBA3), is a member of the APBA family that was identified
as an FIH-1-binding factor that cooperates with the CPT of
MT1-MMP to inhibit FIH-1 in cells.(39) Mint3 shares common
C-terminal domain structures composed of a phosphotyrosine
binding (PTB) domain and 2 PDZ domains, whereas the N-ter-
minus portion is unique to each member protein. The C-terminal
domain of Mint3 is responsible for anchoring it to the cytoplas-
mic domain of transmembrane proteins, such as amyloid precur-
sor protein and furin.(49,50) Consistent with the localization of
these proteins to the Golgi apparatus, Mint3 also localizes
there.(49,51) Because furin serves as a proteolytic activator of
proMT1-MMP before it is transported to the cell surface, Mint3
that binds to the cytoplasmic portion of furin presumably local-
izes in close proximity to the CPT of MT1-MMP in the Golgi
apparatus.(52) The N-terminal portion of Mint3 has a naturally
denatured structure and competes with HIFa for binding FIH-1
and thereby inhibits the hydroxylation of HIFa by FIH-1.(39)
Mint3 is ubiquitously expressed, although some cancer cells
express the protein at relatively higher levels.(53) However,
Mint3 does not inhibit FIH-1 when MT1-MMP is absent.
Genetic depletion of Mint3 (Mint3-KO) in mice does not exhi-
bit severe phenotypes, except for macrophages that exhibit an
ATP shortage, similarly to MT1-KO cells.(45,54,55) Even though
Mint3 expression is ubiquitous, it requires MT1-MMP to inhi-
bit FIH-1, and during inhibition, these three factors co-localize
at the Golgi apparatus. Without MT1-MMP, FIH-1 localizes to
the cytoplasm and Mint3 localizes to the Golgi apparatus.(12)
The CPT of MT1-MMP binds FIH-1 in a sequence-specific
manner and helps recruit cytoplasmic FIH-1 to the Golgi appa-
ratus.(12) The recruited FIH-1 is successively inhibited by the
neighboring Mint3 protein by forming a stable complex.
Translocation of FIH-1 from the cytoplasm to the Golgi upon
MT1-MMP expression in cells was clearly observed by
immunostaining.(12) The CPT of MT1-MMP is composed of








PHDs OH OH FIH-1OH
MT1-MMP/Mint3 axis
Fig. 2. Oxygen-dependent HIF-1a regulation by prolyl hydroxylase
domain (PHD) and FIH-1. bHLH, basic helix-loop-helix; CTAD, C-term-
inal transactivation domain; NTAD, N-terminal transactivation domain;
PAS, Per-Arnt-Sim
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membrane-type MMPs (MT2-MMP, MT3-MMP and MT5-
MMP), but the amino acid residues responsible for FIH-1
binding and HIF activation are specific to MT1-MMP.(12)
Crosstalk of MT1-MMP-mediated Hypoxia-inducible Factor
Activation with Oncogenic Signals
Mint3 can be phosphorylated at the N-terminus by the mTOR
complex 1 (mTORC1), which increases its interaction with
FIH-1 in cells.(47) This finding indicates that MT1-MMP-
mediated HIF activation is affected by the phosphoinositide 3-
kinase (PI3K)/Akt signaling pathway, which is usually acti-
vated in cancer cells.(56) In addition, N-terminal EF-hand cal-
cium binding protein 3 (NECAB3), which structurally
resembles monooxygenase, binds to the PTB domain of Mint3
and promotes Mint3-FIH-1 interactions in cells.(53) The
monooxygenase activity of NECAB3 is presumably necessary
for this function, but the precise mechanism remains unclear.
Thus, further studies are needed to clarify the mechanism
whereby NECAB3 promotes Mint3-FIH-1 interaction in coop-
eration with oncogenic signals.
PI3K/Akt is reported to augment HIF-1a translation via
mTOR activation. (38) However, it may not contribute to HIF-
1a transcription activity so far as FIH-1 remains suppressive.
Thus, oncogenic signals that activate MT1-MMP and PI3K/
Akt cooperatively use the Mint3/FIH-1 axis and mTOR to acti-
vate HIF effectively (Fig. 3).
In addition to HIFa, FIH-1 can hydroxylate the inhibitor of
jBa (IjBa), which inhibits nuclear factor jB (NF-jB).(57) NF-
jB is involved in inflammatory responses and plays an impor-
tant role in tumor development.(58,59) Interestingly, IjBa is
accumulated in Mint3-KO macrophages.(55) Thus, the MT1-
MMP/Mint3/FIH-1 axis might also control cellular NF-jB sig-
naling via IjBa.
Effect of Hypoxia-inducible Factor Activation on
Tumorigenesis
The Warburg effect in cancer cells was reported a century
ago(42) and this characteristic phenomenon is applied to cancer
diagnosis using the glucose derivative 18F-fludeoxyglucose and
positron-emission tomography scanning.(60) Nevertheless, the
impact of the phenomenon on cancer is not necessarily clear
because of its complexity. One explanation is that elevated
glucose uptake increases the supply of carbon blocks for
rapidly dividing cancer cells that need to double their cellular
components.(43) Another possibility is that reduced oxygen
consumption in the normoxic tumor mass area may save avail-
able oxygen for the inner cells to mitigate hypoxic stress.(16)
Among cancer cell lines, invasive cells usually exhibit the
Warburg effect, while non-invasive cell lines rarely do so. A
pair of human breast carcinoma cell lines was used to analyze
the Warburg effect.(60) The invasive cell MDA-MB-231 line
showed elevated glycolytic activity, whereas the non-invasive
MCF-7 cell line did not, and these activities correlated with
HIF-1 activity and cellular MT1-MMP expression.(48) Gene-
expression knockdown experiments demonstrated that HIF-1
activity in MDA-MB-231 cells reflect MT1-MMP and Mint3
dependent FIH-1 inactivation, whereas Mint3 did not inhibit
FIH-1 in MCF-7 cells.(48) Therefore, the MT1-MMP/Mint3/
FIH-1 axis operates in MDA-MB-231 cells to overcome inhibi-
tion of HIF activity and activate glycolysis. MT1-MMP was
expressed in 10 out of 14 human cancer cell lines tested,
where lactate production representing glycolysis and HIF-1
activity was upregulated via Mint3-dependent FIH-1 inactiva-
tion.(48) However, the remaining 4 cell lines showed lower lac-
tate production and negligible MT1-MMP expression.(48)
Therefore, a clear correlation was demonstrated between MT1-
MMP expression, FIH-1 inactivation and elevated glycolysis in
cancer cells. Mint3 knockdown using short hairpin RNA in
MDA-MB-231 cells abrogated MT1-MMP-dependent HIF-1
activation and reduced both tumor formation in mice and
blood vessel density in tumor tissue.(48)
Von Hippel–Lindau syndrome is a representative case that
indicates the importance of HIF activity in tumor develop-
ment.(37) In this syndrome, the VHL gene is genetically inacti-
vated, which results in constitutively high HIF activity.
Patients with the disease develop different types of tumors,
such as hemangioblastomas, kidney cancer and pancreatic can-
cer,(37) indicating that HIF activity may increase the rate of
tumor development in the disease. In addition, HIF promote
malignant conversion of cancer cells by enhancing cell motil-
ity and invasion via upregulating multiple genes.(18)
Because HIF are potent modulators of tumor malignance,
they have been regarded as potential targets for cancer therapy.
However, the global inhibition of HIF affects their physiologi-
cal functions, such as hypoxia response.(61–63) Because MT1-
MMP-dependent activation of HIF is mostly specific to malig-
nant cancer cells and activated stromal cells,(12,48) targeting the
MT1-MMP/Mint3/FIH-1 axis is more specific and appropriate
for cancer therapy. Application of pathway-specific inhibitors
might be suitable for treating patients, in particular for pre-
venting tumor recurrence when residual cancer cells start to
grow again.
Intervention of Hypoxia-inducible Factor Activation by
MT1-MMP in Stromal Cells
Most cells produce ATP via OXPHOS in the mitochondria,
but macrophages mainly utilize glycolysis for ATP production,
even during normoxia.(40) Among leukocytes, MT1-MMP is
expressed in macrophages.(11) MT1-MMP-deficient and Mint3-
deficient macrophages exhibit decreased expression of HIF-1
target genes, ATP production and ATP-dependent cellular
functions, such as motility, invasion and cytokine produc-
tion.(11,12,45,54) In cancer, tumor-associated macrophages


























Fig. 3. Hypoxia-inducible factors (HIF) activation by oncogenic muta-
tions and MT1-MMP. Many oncogenic mutations cause accumulation
of the HIFa protein. However, the HIFa protein is inactivated as a tran-
scription factor when hydroxylated by FIH-1. MT1-MMP and Mint3
evade this suppressive mechanism.
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metastasis.(64) Thus, targeting the MT1-MMP/Mint3 axis might
also control TAM-mediated tumor malignancy.
Other than macrophages, fibroblasts also show increased
expression of HIF-1 target genes due to MT1-MMP activity
during normoxia.(12) Fibroblasts are one of the major cell types
constituting the various types of tumor tissues, and cancer-
associated fibroblasts (CAF) are known to regulate tumor
growth, metastasis and drug resistance.(65,66) Thus, CAF are
also potential target cells of anti-MT1-MMP-mediated HIF-
activation therapy.
Conclusion
The MT1-MMP proteinase has been characterized as one of
the key regulators of cancer cell proliferation, invasion and
metastasis. In addition, MT1-MMP activates HIF transcription
factors independently of its proteinase activity, as reviewed
above. In physiological settings, such as during wound healing,
epithelial cells can exhibit EMT and activated stromal cells
start to express MT1-MMP, which promotes their proliferation
and migration. In invasive cancer cells, MT1-MMP expression
is turned on by oncogenic and EMT-inducing signals. MT1-
MMP activity promotes cellular invasion and proliferation by
processing key substrates and also by activating HIF transcrip-
tion factors through a CPT-dependent mechanism. Thus, extra-
cellular protease activity and the intracellular non-protease
activity are collectively integrated into malignant cancer phe-
notypes (Fig. 4). Systemic inhibition of the protease activity of
MT1-MMP might cause fibrosis, as observed for MT1-KO
mice.(28,29) In addition, MT1-MMP proteinase inhibitors cannot
suppress the intracellular non-protease activity of MT1-MMP.
Thus, targeting both the focused proteolytic function and the
non-proteolytic function of MT1-MMP may be preferable for
blocking MT1-MMP-mediated malignant cancer phenotypes
completely without adverse effects. HIF-1 activation in cancer
cells itself is important for tumorigenicity and invasion/metas-
tasis, and inhibition of the HIF-activation pathway by MT1-
MMP is an attractive new approach for developing cancer
therapeutics. We think that specifically inhibiting HIF-1 activa-
tion is better for cancer treatment than global HIF inhibition
because a more targeted approach may avoid unnecessary
adverse effects. Inhibitors targeting the MT1-MMP/Mint3/FIH-
1 axis might be suitable for preventing recurrence in cancer
patients following treatment with standard therapy. However,
large tumors that contain hypoxic areas inside may not be
good targets, as the effect of inhibiting the MT1-MMP-depen-
dent axis is presumably overwhelmed by responses to hypoxia.
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